The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...

New treatment builds on Pfizer’s migraine portfolio to further meet the needs of people living with this debilitating disease ...